News

Alfa Laval Reports Fourth Quarter and Year-End Financials

Alfa Laval Reports Fourth Quarter and Year-End Financials

Financial Highlights for Alfa Laval

In recent financial disclosures, Alfa Laval AB has presented insights into their order intake and net sales. The company's order intake amounted to SEK 17.1 billion, reflecting an 8 percent decline compared to the previous year. Among this, the organic decline was 2 percent. On the positive side, net sales experienced a surge of 5 percent, reaching SEK 19.1 billion, pushing the organic growth up by 11 percent.

Fourth Quarter Performance

For the fourth quarter, the order intake reported was SEK 17.1 billion, showing a decline of 2 percent year-over-year. However, the net sales increased to SEK 19.1 billion, demonstrating a robust organic growth of 11 percent. The adjusted EBITA for this period reached SEK 3.2 billion, marking an 11 percent rise. Notably, the EBITA margin also improved to 16.9 percent compared to last year’s 16.0 percent.

Financial Breakdown of Fourth Quarter

An analysis of the fourth quarter reveals a decline in order intake to SEK 17,081 million, contrasted with an increase in net sales to SEK 19,146 million. The adjusted EBITA stood at SEK 3,237 million. The result after financial items was SEK 2,865 million, and the net income for this period was SEK 1,991 million, leading to earnings per share of SEK 4.79. Cash flow from operating activities showed a significant drop, amounting to SEK 3,396 million.

Full Year Overview

Transitioning to the full year summary, the overall order intake saw a larger decline of 6 percent, totaling SEK 66,742 million. However, net sales surged to SEK 69,674 million, reflecting an 8 percent increase. The adjusted EBITA for the entire year was reported at SEK 12,334 million, up from 11,089 million last year. This resulted in an improved adjusted EBITA margin of 17.7 percent.

Full Year Financial Highlights

The complete annual report illustrated that the result after financial items climbed to SEK 11,198 million, with net income reaching approximately SEK 8,322 million, resulting in earnings per share of SEK 20.01. A noticeable decrease in cash flow from operating activities was noted, totaling SEK 9,166 million compared to 12,778 million before. Additionally, the return on capital employed was a healthy 23.9 percent, and the net debt to EBITDA ratio was 0.92, indicating a strong financial basis.

Future Outlook

Looking ahead into the first quarter, the company projects that demand levels will likely match those observed in the fourth quarter. This outlook showcases the company's cautious but optimistic view regarding market performance in the immediate future.

Recent Developments

Alfa Laval continues to innovate and adapt within the industry, focusing on improving efficiency and meeting customer needs more effectively. The leadership team remains committed to driving sustainable growth and maximizing shareholder value.

Contact Information

For further inquiries, Johan Lundin, Head of Investor Relations, can be reached via phone or mobile. While specific email details have been omitted for privacy, you can reach out through other provided channels.

Frequently Asked Questions

What was the order intake for Alfa Laval in the fourth quarter?

The order intake for the fourth quarter was SEK 17.1 billion, reflecting a decline of 2 percent compared to the previous year.

How did net sales change for the full year?

Net sales for the full year increased by 8 percent, reaching SEK 69,674 million, compared to 66,954 million in the prior year.

What is the adjusted EBITA margin for the year?

The adjusted EBITA margin for the full year improved to 17.7 percent from 16.6 percent the previous year.

What expectations does Alfa Laval have for the first quarter?

The company expects demand in the first quarter to remain on par with the levels experienced in the fourth quarter.

Who should I contact for investor inquiries at Alfa Laval?

Johan Lundin, Head of Investor Relations, can be contacted for investor inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Horowitz's $150M Boost for Nevada's First Children's Hospital

Updated Category News Views 97

Big Bucks and Bigger Hearts Boost Pediatric Care in Nevada The world isn't exactly short on folks looking to make a buck, but every so often, someone comes along and wants to make a difference instead. Enter Felicia and Ben Horowitz, handing over a staggering $150 million to Intermountain Health. This isn’t your garden-variety gift—it’s aimed at getting Nevada on...

Continue Reading
UCB's Endowment Marks New Era in Medicine Evaluation

Updated Category News Views 60

Stepping into a New Chapter for Medicine Evaluation UCB's latest move smacks of a strategic vision that's not just about immediate returns—it's a long game in pharmacoepidemiology. You don't see investors lining up for this news, but this chair at Brigham and Women's is bigger than it looks. By establishing the Emmanuel Janssen Endowed Chair, UCB is underpinning the...

Continue Reading
Steady Income Boosts FHLBank Boston's Growth Q3 2026

Updated Category News Views 50

The Federal Home Loan Bank of Boston dropped their third-quarter results for 2026 like a hot smokestack, and let me tell you, it's a mixed bag of cautious optimism and steady progression. It's essentially proof that slow and steady might just win the race—or at least keep you in the running. Stable and Steady Headway Taking a peek under the hood, FHLBank Boston made a...

Continue Reading
Wisconsin Brats Clash with Florida Citrus in Marketing Showdown

Updated Category News Views 14

A Juicy Rivalry with Sweet and Savory Stakes You ever catch yourself watching state pride turn into a marketing showdown? That's what's cookin' with Wisconsin's Johnsonville and Florida's Natural, and believe me, this isn't just about what’s on your plate. Forget the foam fingers, here it's all about the brats and the OJ. It's like the Packers versus the Dolphins, but...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 28

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Patrick Ta Beauty Adds New Leadership to Expand Growth

Updated Category News Views 36

Angela Simpson and Carolyne Rapp Join the Ranks In the fast-paced world of beauty, where trends shift faster than a day trader’s mood, Patrick Ta Beauty is shaking things up with some heavyweight hires. Angela Simpson steps in as Chief Marketing Officer, and Carolyne Rapp takes the reins as Vice President of Creative. Maybe it’s just me, but when a brand ropes in pros...

Continue Reading
Lunit, Summit Tackle Tumor Analysis with AI Platform

Updated Category News Views 168

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...

Continue Reading
Hyperliquid Reports Q3 2026 Results with Webcast Insights

Updated Category News Views 74

Unlocking Hyperliquid’s Third Quarter Performance It's time to grab your investing gear because Hyperliquid Strategies Inc is ready to spill the beans on their Q3 2026 performance. The digital asset treasury focused on the hyperventilating HYPE token—fined-tuned to serve US and institutional investors—is broadcasting a live webcast on November 5, 2026. Mark your...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 57

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Veterans Find Community and Wellness at Orland Hills Bash

Updated Category News Views 16

A Celebration of Veterans and Community Orland Hills is set to light up with a unique Veterans Day Bash on November 1, 2026. This isn't just your run-of-the-mill community gathering; it's an event that brings together veterans from all around for a day packed with resources, education, and a chance to connect with kindred spirits—all thanks to the collaboration between...

Continue Reading

Top 5 Most Recently Viewed Articles

2026 Best Buddies Challenge Hits $4M For Inclusion

Updated Category News Views 7

A Record-Breaking Year for Best Buddies Everyone loves a good underdog story, and every now and then, you get one that really hits home. The 27th Annual Best Buddies Challenge in Hyannis Port did exactly that, raking in a whopping $4 million and drawing a crowd of nearly 1,000 participants. The event serves as both a fundraiser and a community builder, spotlighting its...

Continue Reading
MSP Recovery Implements Reverse Stock Split for Compliance

Updated Category News Views 239

MSP Recovery Announces a Reverse Stock Split MSP Recovery, Inc. (NASDAQ: MSPR), a leader in Medicare, Medicaid, and secondary payer reimbursement recovery, recently announced a reverse stock split of its Class A common stock at a ratio of 1-for-7. This strategic move aims to ensure compliance with Nasdaq's minimum bid price requirement. Details of the Stock Split The...

Continue Reading
The Value of a $1000 Investment in Primerica Over 10 Years

Updated Category News Views 127

Understanding Primerica's Growth Over the Last Decade Primerica Inc (NYSE: PRI) has shown remarkable performance, outperforming the market by an annualized rate of 8.02%. This impressive rate results in an average annual return of 19.51% for the investors over the past ten years. As of now, the company has a market valuation of approximately $8.63 billion, indicating...

Continue Reading
Innovative G-Rex Grants Propel Cell Therapy Manufacturing Growth

Updated Category News Views 161

Innovative G-Rex Grants Propel Cell Therapy Manufacturing Growth ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), has announced an exciting initiative aimed at enhancing cell and gene therapy manufacturing. Eight G-Rex Grants, amounting to nearly $2 million, have been awarded to distinguished recipients within the...

Continue Reading